These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 29478009)

  • 21. Heterogeneous transmural gene expression of calcium-handling proteins and natriuretic peptides in the failing human heart.
    Prestle J; Dieterich S; Preuss M; Bieligk U; Hasenfuss G
    Cardiovasc Res; 1999 Aug; 43(2):323-31. PubMed ID: 10536662
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intramyocardial injection of SERCA2a-expressing lentivirus improves myocardial function in doxorubicin-induced heart failure.
    Mattila M; Koskenvuo J; Söderström M; Eerola K; Savontaus M
    J Gene Med; 2016 Jul; 18(7):124-33. PubMed ID: 27203155
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Current and Future Landscape of SERCA Gene Therapy for Heart Failure: A Clinical Perspective.
    Hayward C; Banner NR; Morley-Smith A; Lyon AR; Harding SE
    Hum Gene Ther; 2015 May; 26(5):293-304. PubMed ID: 25914929
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Heart failure-inducible gene therapy targeting protein phosphatase 1 prevents progressive left ventricular remodeling.
    Miyazaki Y; Ikeda Y; Shiraishi K; Fujimoto SN; Aoyama H; Yoshimura K; Inui M; Hoshijima M; Kasahara H; Aoki H; Matsuzaki M
    PLoS One; 2012; 7(4):e35875. PubMed ID: 22558250
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Gene therapy in heart failure: the unexpected results from the CUPID 2 trial].
    Gigli M; Sinagra G; Mestroni L
    G Ital Cardiol (Rome); 2017 Feb; 18(2):101-105. PubMed ID: 28398363
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gene therapy in heart failure. SERCA2a as a therapeutic target.
    Hayward C; Patel H; Lyon A
    Circ J; 2014; 78(11):2577-87. PubMed ID: 25327883
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Investigation of the safety and feasibility of AAV1/SERCA2a gene transfer in patients with chronic heart failure supported with a left ventricular assist device - the SERCA-LVAD TRIAL.
    Lyon AR; Babalis D; Morley-Smith AC; Hedger M; Suarez Barrientos A; Foldes G; Couch LS; Chowdhury RA; Tzortzis KN; Peters NS; Rog-Zielinska EA; Yang HY; Welch S; Bowles CT; Rahman Haley S; Bell AR; Rice A; Sasikaran T; Johnson NA; Falaschetti E; Parameshwar J; Lewis C; Tsui S; Simon A; Pepper J; Rudy JJ; Zsebo KM; Macleod KT; Terracciano CM; Hajjar RJ; Banner N; Harding SE
    Gene Ther; 2020 Dec; 27(12):579-590. PubMed ID: 32669717
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Overexpression of sarcoplasmic reticulum calcium ATPase induced hemodynamic and proteomic changes in a dog model of heart failure].
    Fu ZQ; Li XY; Liu XH; Sun S; Liu T; Mi YF; Zhou SA; Ye WH; Wang QS
    Zhonghua Xin Xue Guan Bing Za Zhi; 2008 Mar; 36(3):260-5. PubMed ID: 19099986
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The function and significance of SERA2a in congestive heart failure: an analysis of gene therapy trials.
    Wu P; Zhai Y; Li D
    Histol Histopathol; 2017 Aug; 32(8):767-777. PubMed ID: 28134413
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correcting Calcium Dysregulation in Chronic Heart Failure Using SERCA2a Gene Therapy.
    Samuel TJ; Rosenberry RP; Lee S; Pan Z
    Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29621141
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improvement in survival and cardiac metabolism after gene transfer of sarcoplasmic reticulum Ca(2+)-ATPase in a rat model of heart failure.
    del Monte F; Williams E; Lebeche D; Schmidt U; Rosenzweig A; Gwathmey JK; Lewandowski ED; Hajjar RJ
    Circulation; 2001 Sep; 104(12):1424-9. PubMed ID: 11560860
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiac SERCA2A/B: therapeutic targets for heart failure.
    Shareef MA; Anwer LA; Poizat C
    Eur J Pharmacol; 2014 Feb; 724():1-8. PubMed ID: 24361307
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Benefit of SERCA2a gene transfer to vascular endothelial and smooth muscle cells: a new aspect in therapy of cardiovascular diseases.
    Lipskaia L; Hadri L; Lopez JJ; Hajjar RJ; Bobe R
    Curr Vasc Pharmacol; 2013 Jul; 11(4):465-79. PubMed ID: 23905641
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Treatment of chronic heart failure by overexpressing sarcoplasmic reticulum calcium ATPase through gene therapy: an experiment with rats].
    Li XY; Hui HP; Lu XC; Guo YT
    Zhonghua Yi Xue Za Zhi; 2006 May; 86(17):1174-8. PubMed ID: 16796857
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The cardiac sarcoplasmic/endoplasmic reticulum calcium ATPase: a potent target for cardiovascular diseases.
    Kawase Y; Hajjar RJ
    Nat Clin Pract Cardiovasc Med; 2008 Sep; 5(9):554-65. PubMed ID: 18665137
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular targets in heart failure gene therapy: current controversies and translational perspectives.
    Kairouz V; Lipskaia L; Hajjar RJ; Chemaly ER
    Ann N Y Acad Sci; 2012 Apr; 1254():42-50. PubMed ID: 22548568
    [TBL] [Abstract][Full Text] [Related]  

  • 37. B-type natriuretic peptide and its role in altering Ca
    Zhao J; Xu T; Zhou Y; Zhou Y; Xia Y; Li D
    Heart Fail Rev; 2020 Sep; 25(5):861-871. PubMed ID: 31820203
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Augmentation of left ventricular mechanics by recirculation-mediated AAV2/1-SERCA2a gene delivery in experimental heart failure.
    Mariani JA; Smolic A; Preovolos A; Byrne MJ; Power JM; Kaye DM
    Eur J Heart Fail; 2011 Mar; 13(3):247-53. PubMed ID: 21289077
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interleukin-17 upregulation participates in the pathogenesis of heart failure in mice via NF-κB-dependent suppression of SERCA2a and Cav1.2 expression.
    Xue GL; Li DS; Wang ZY; Liu Y; Yang JM; Li CZ; Li XD; Ma JD; Zhang MM; Lu YJ; Li Y; Yang BF; Pan ZW
    Acta Pharmacol Sin; 2021 Nov; 42(11):1780-1789. PubMed ID: 33589793
    [TBL] [Abstract][Full Text] [Related]  

  • 40. How B-Type Natriuretic Peptide (BNP) and Body Weight Changes Vary in Heart Failure With Preserved Ejection Fraction Compared With Reduced Ejection Fraction: Secondary Results of the HABIT (HF Assessment With BNP in the Home) Trial.
    Maisel AS; Shah KS; Barnard D; Jaski B; Frivold G; Marais J; Azer M; Miyamoto MI; Lombardo D; Kelsay D; Iqbal N; Taub PR; Kupfer K; Lee E; Clopton P; Zile M; Greenberg B
    J Card Fail; 2016 Apr; 22(4):283-93. PubMed ID: 26433086
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.